Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy Academic Article uri icon

Overview

MeSH Major

  • Hypoglycemic Agents
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Receptors, Cytoplasmic and Nuclear
  • Thiazolidinediones
  • Transcription Factors

abstract

  • Rosiglitazone did not increase PSADT or prolong the time to disease progression more than placebo in men with a rising PSA level after radical prostatectomy and/or radiation therapy. The unexpected discordance between baseline and posttreatment PSADT in the placebo group reinforced the importance of randomized controlled trials in this setting.

publication date

  • October 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.20493

PubMed ID

  • 15468186

Additional Document Info

start page

  • 1569

end page

  • 74

volume

  • 101

number

  • 7